Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

972 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.
Rosás-Umbert M, Ruiz-Riol M, Fernández MA, Marszalek M, Coll P, Manzardo C, Cedeño S, Miró JM, Clotet B, Hanke T, Moltó J, Mothe B, Brander C; BCN02 study group. Rosás-Umbert M, et al. Among authors: miro jm. Front Immunol. 2020 Mar 20;11:418. doi: 10.3389/fimmu.2020.00418. eCollection 2020. Front Immunol. 2020. PMID: 32265913 Free PMC article. Clinical Trial.
The changing face of HIV/AIDS in treated patients.
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. Llibre JM, et al. Among authors: miro jm. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633. Curr HIV Res. 2009. PMID: 19601771 Review.
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group. Miró JM, et al. AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105. AIDS Res Hum Retroviruses. 2010. PMID: 20624069 Clinical Trial.
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
Gil C, Climent N, García F, Hurtado C, Nieto-Márquez S, León A, García MT, Rovira C, Miralles L, Dalmau J, Pumarola T, Almela M, Martinez-Picado J, Lifson JD, Zamora L, Miró JM, Brander C, Clotet B, Gallart T, Gatell JM. Gil C, et al. Among authors: miro jm. Vaccine. 2011 Aug 5;29(34):5711-24. doi: 10.1016/j.vaccine.2011.05.096. Epub 2011 Jun 14. Vaccine. 2011. PMID: 21679735 Clinical Trial.
Renal dysfunction in the setting of HIV/AIDS.
Miro JM, Cofan F, Trullas JC, Manzardo C, Cervera C, Tuset M, Oppenheimer F, Brunet M, Moreno A, Campistol JM, Gatell JM. Miro JM, et al. Curr HIV/AIDS Rep. 2012 Sep;9(3):187-99. doi: 10.1007/s11904-012-0125-9. Curr HIV/AIDS Rep. 2012. PMID: 22706955 Review.
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators. Kawana-Tachikawa A, et al. Among authors: miro jm. PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014. PLoS One. 2014. PMID: 24475275 Free PMC article. Clinical Trial.
972 results